TD Cowen initiated coverage on shares of Biodesix (NASDAQ:BDSX - Free Report) in a research report sent to investors on Monday, Marketbeat.com reports. The firm issued a buy rating and a $2.80 target price on the stock.
BDSX has been the subject of several other research reports. Canaccord Genuity Group reaffirmed a buy rating and issued a $3.50 price objective on shares of Biodesix in a report on Monday, March 4th. Lake Street Capital began coverage on shares of Biodesix in a report on Friday, May 3rd. They issued a buy rating and a $3.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Biodesix has a consensus rating of Buy and a consensus target price of $3.10.
View Our Latest Report on Biodesix
Biodesix Stock Performance
BDSX stock traded down $0.06 during trading on Monday, hitting $1.52. 95,781 shares of the company's stock traded hands, compared to its average volume of 140,077. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 7.69. Biodesix has a 52 week low of $1.03 and a 52 week high of $2.21. The stock has a fifty day moving average price of $1.39 and a two-hundred day moving average price of $1.57. The stock has a market capitalization of $174.33 million, a price-to-earnings ratio of -2.77 and a beta of 1.15.
Biodesix (NASDAQ:BDSX - Get Free Report) last released its quarterly earnings results on Friday, March 1st. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $14.67 million during the quarter, compared to analyst estimates of $15.76 million. Biodesix had a negative net margin of 85.80% and a negative return on equity of 29,379.44%. As a group, equities analysts anticipate that Biodesix will post -0.44 EPS for the current fiscal year.
Institutional Investors Weigh In On Biodesix
A number of institutional investors and hedge funds have recently bought and sold shares of BDSX. Oracle Investment Management Inc. acquired a new stake in Biodesix in the 3rd quarter valued at about $69,000. Opaleye Management Inc. lifted its holdings in Biodesix by 9.0% in the 4th quarter. Opaleye Management Inc. now owns 496,500 shares of the company's stock valued at $914,000 after acquiring an additional 40,927 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its holdings in Biodesix by 1.4% in the 1st quarter. Essex Investment Management Co. LLC now owns 925,614 shares of the company's stock valued at $1,324,000 after acquiring an additional 12,669 shares during the last quarter. 20.96% of the stock is owned by institutional investors and hedge funds.
About Biodesix
(
Get Free Report)
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
See Also
Before you consider Biodesix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.
While Biodesix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
